Regeneron Pharmaceuticals Inc. buy Maxi_Scalibusa
Start price
02.08.18
/
50%
€358.38
Target price
24.05.19
€857.35
Performance (%)
-21.11%
End price
24.05.19
€282.73
Summary
This prediction ended on 24.05.19 with a price of €282.73. The prediction for Regeneron Pharmaceuticals Inc. disappointed with a performance of -21.11%. Maxi_Scalibusa has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.288% | 1.288% | 39.535% | -5.284% |
| iShares Core DAX® | -1.586% | 5.028% | 6.332% | 64.061% |
| iShares Nasdaq 100 | -4.148% | -0.125% | 25.735% | 86.918% |
| iShares Nikkei 225® | -6.302% | 0.528% | 41.384% | 77.872% |
| iShares S&P 500 | -3.225% | 0.470% | 20.449% | 68.192% |
Comments by Maxi_Scalibusa for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
(Vom Mitglied beendet)